Laguna Hills, United States
PreludeDx is a biotechnology company founded in 2009 with a focus on delivering actionable tools for managing early-stage breast cancer. The company's first diagnostic test, DCISionRT, is the result of over a decade of research and development, initially inspired by technology licensed from the University of California, San Francisco. DCISionRT addresses the crucial question faced by patients with DCIS - assessing the risk of recurrence and determining the appropriate treatment.
Operating within the biotechnology, health care, and pharmaceutical industries, PreludeDx is headquartered in the United States. In March 22, 2022, the company received a significant $20.00M Venture Round investment from Evidity Health Capital.
This recent investment underscores the recognition and support garnered by PreludeDx's innovative approach to addressing a critical gap in early-stage breast cancer management. As the company continues to advance its pioneering diagnostic solutions, it is positioned for ongoing impact and growth within the healthcare industry.
